
Ask a doctor about a prescription for Viread 33 mg/g GRANULES
Package Leaflet: Information for the Patient
Viread 33 mg/g Granules
Tenofovir Disoproxil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
If Viread has been prescribed to your child, note that all the information in this leaflet is intended for your child (in this case, read “your child” instead of “you”).
Viread contains the active substance tenofovir disoproxil. This active substance is an antiretroviral or antiviral medicine used to treat HIV or HBV, or both. Tenofovir is a nucleotide analogue reverse transcriptase inhibitor, commonly known as NtRTI, which works by interfering with the normal function of enzymes (in the case of HIV, reverse transcriptase, and in hepatitis B, DNA polymerase) that are essential for the viruses to reproduce.
For the treatment of HIV infection, Viread must always be used in combination with other medicines.
Viread 33 mg/g granules is a medicine used to treat HIV infection(Human Immunodeficiency Virus). It is suitable for:
Viread 33 mg/g granules is also a medicine used to treat chronic hepatitis B, an infection caused by the HBV(hepatitis B virus). It is suitable for:
You do not need to have HIV to be treated with Viread for HBV.
This medicine is not a cure for HIV infection. While you are taking Viread, you may still develop infections or other illnesses associated with HIV. You may also continue to transmit HIV or HBV to others. Therefore, it is important that you take precautions to avoid infecting others.
Do not take Viread
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Viread.
Viread is not normally taken with other medicines that can harm your kidneys (see Taking Viread with other medicines). If this is unavoidable, your doctor will check your kidney function once a week.
Bone problems (sometimes resulting in fractures) may also occur due to damage to the renal tubular cells (see section 4, Possible side effects).
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection.
Autoimmune disorders can occur many months after starting treatment. If you observe any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors, or hyperactivity, inform your doctor immediately to receive the necessary treatment.
Children and adolescents
Viread 33 mg/g granules are only suitablefor:
Viread 33 mg/g granules are notsuitable for the following groups:
For dosing information, see section 3, How to take Viread.
Other medicines and Viread
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
These medicines include:
Taking Viread with food and drinks
Viread granules must be mixed with soft foods that do not require chewing(e.g., yogurt, applesauce, or mashed potatoes). If the granule mixture is chewed, it will have a very bitter taste.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Viread may cause dizziness. If you feel dizzy during treatment with Viread, do not drive or ride a bicycleor operate tools or machines.
Viread granules contain mannitol
Mannitol may have a mild laxative effect.
Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, talk to your doctor or pharmacist again.
The recommended dose is:
Viread granules must be measured with the dosing scoop provided (see Figure A):
Each level dosing scoop administers 1 g of granules containing 33 mg of tenofovir disoproxil (as fumarate).



Consult the leaflets of the other antiretrovirals to find out how to take these medicines.
If you take more Viread than you should
If you have accidentally taken too much Viread, you may be at greater risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). Talk to your doctor or go to the nearest emergency department. Take the jar of granules with you so that you can easily describe what you have taken.
If you forget to take Viread
It is important that you do not miss a dose of Viread. If you miss a dose, determine how long it has been since you should have taken it.
If you vomit before 1 hour has passed after taking Viread,take another dose. You do not need to take another dose if you vomit more than 1 hour after taking Viread.
If you stop taking Viread
Do not stop taking Viread without talking to your doctor. Stopping treatment with Viread may reduce the effectiveness of the treatment recommended by your doctor.
If you have hepatitis B, or HIV and hepatitis B (co-infection),it is very important that you do not stop your treatment with Viread without first talking to your doctor. After stopping treatment with Viread, some patients have had blood tests or symptoms indicating that their hepatitis had worsened. You may need to have blood tests for several months after stopping treatment. In patients with advanced liver disease or cirrhosis, it is not recommended to stop treatment as this may lead to worsening of hepatitis.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause adverse effects, although not all people experience them.
Possible Serious Adverse Effects: Inform Your Doctor Immediately
Other Possible Serious Adverse Effects
The following adverse effects are uncommon(may affect up to 1 in 100 patients):
The following adverse effects are rare(may affect up to 1 in 1,000 patients):
More Frequent Adverse Effects
The following adverse effects are very common(may affect at least 10 in 100 patients):
Lab tests may also show:
Other Possible Adverse Effects
The following adverse effects are common(may affect up to 10 in 100 patients):
Lab tests may also show:
The following adverse effects are uncommon(may affect up to 1 in 100 patients):
Lab tests may also show:
Muscle rupture, bone weakening (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness, and decreased blood potassium or phosphate levels may occur due to kidney tubule cell damage.
The following adverse effects are rare(may affect up to 1 in 1,000 patients):
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system listed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the bottle and carton after CAD. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Viread Composition
Product Appearance and Package Contents
This medication consists of a white, coated granule. The granules are supplied in a bottle containing 60 g of granules and are packaged with a dosing spoon.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medication from the local representative of the Marketing Authorization Holder:
België/Belgique/Belgien Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 | Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
?????? Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg/Luxemburg Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 |
Ceská republika Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Magyarország Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 |
Ελλ?δα Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Österreich Gilead Sciences GesmbH Tel: + 43 1 260 830 |
España Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tél: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | România Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ísland Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849 | Slovenská republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italia Gilead Sciences S.r.l. Tel: + 39 02 439201 | Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849 |
Κ?προς Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Date of Last Revision of this Leaflet: {MM/AAAA}
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Viread 33 mg/g GRANULES – subject to medical assessment and local rules.